MYD88 mutated and wild-type Waldenströms Macroglobulinemia: Characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4
Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia
BTKCys481Ser drives ibrutinib resistance via ERK1/2, and protects BTKWild-Type MYD88 mutated cells by a paracrine mechanism
The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma
The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma
Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival
Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas
Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma
MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia
